Scott Adams Battles Prostate Cancer, Receives New Drug Approval After Trump's Response
Dilbert creator Scott Adams is fighting late-stage prostate cancer and sought President Trump's help to access the new FDA-approved drug Pluvicto, which his healthcare provider later approved.
Overview
- Scott Adams, the creator of the popular "Dilbert" comic strip, is currently battling late-stage prostate cancer that has metastasized.
- He sought access to Pluvicto, a new FDA-approved drug, for his advanced prostate cancer, encountering initial delays with his healthcare provider.
- Adams publicly appealed for assistance, specifically reaching out to President Trump for help in obtaining the crucial new treatment.
- President Trump responded to Adams's plea, acknowledging his situation and offering support in his fight against the aggressive cancer.
- Ultimately, Adams's healthcare provider approved his application to receive the new FDA-approved drug Pluvicto, allowing him to proceed with treatment.
Report issue
Read both sides in 5 minutes each day
Analysis
Analysis unavailable for this viewpoint.
Articles (3)
Center (0)
No articles found in the Center category
FAQ
Pluvicto (177Lu-PSMA-617) is a radioligand therapy that delivers targeted radiation directly to prostate cancer cells expressing prostate-specific membrane antigen (PSMA). It consists of a radioactive isotope, Lutetium-177, attached to a molecule that binds to PSMA, allowing it to selectively destroy cancer cells while minimizing damage to healthy tissue.
Scott Adams's case drew attention because he publicly appealed for access to Pluvicto, a newly FDA-approved drug for advanced prostate cancer, after facing initial delays from his healthcare provider. His appeal, including a request for help from President Trump, highlighted challenges some patients face in accessing cutting-edge treatments.
Patients must have PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), have been treated with an androgen receptor pathway inhibitor (ARPI), and be considered appropriate to delay taxane-based chemotherapy. Eligibility is confirmed using a PSMA PET scan, such as with Locametz, to identify PSMA expression in tumors.
Pluvicto offers a targeted approach, delivering radiation directly to cancer cells, which can improve survival and quality of life compared to traditional chemotherapy. Recent trials show it significantly reduces the risk of disease progression or death and can be used earlier in treatment, before chemotherapy, expanding options for patients.
Common side effects of Pluvicto include fatigue, nausea, decreased appetite, and low blood cell counts. Serious adverse events should be reported to the FDA's MedWatch system. Healthcare providers monitor patients closely during treatment.
History
- This story does not have any previous versions.